CARMAT :'s Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization
05/07/2021 | 01:01am EDT
Send by mail :
Message :
Required fields
The Board of Directors warmly thanks Dr. Philippe Pouletty, Managing Director of Truffle Capital, for his exceptional contribution to the development of the CARMAT project, and proposes the appointment of three new directors, Florent Battistella, David Coti and John B. Hernandez.
Regulatory News:
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announced today the reorganization of its governance with the proposed appointment of Florent Battistella, David Coti and John B. Hernandez as directors. These appointments will be submitted for approval at the upcoming General Meeting of CARMAT at May 12, 2021.